Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. Equillium, Inc. has a research collaboration agreement with Vivtex Corporation to develop GI-targeted formulations for Bi-specific peptide therapy. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Market Cap	$86.87M	P/E Ratio	NaN
52W High	$2.35	52W Low	$0.27
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	44.7%	52W Position	61.5%
Overall Score	56	Value Score	60
Quality Score	44	Technical Score	66

EPS Current Est	$NA	EPS Next Est	$NA
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	EQ	$1.55	+1.97%	443.20K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	EQ	$1.55	+2.0%	443.20K
3
4
5
6

EQ

EQ

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Equillium Inc. Data in Excel

Get Equillium Inc. Data in Excel